US · SYBX
Synlogic, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02142
- Website
- synlogictx.com
Price · as of 2024-12-31
—
Market cap 18.95M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $41.98 | — |
| Intrinsic Value(DCF) | $0.53 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $167.26 | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $457.80 | ||||
| 2016 | $229.95 | ||||
| 2017 | $168.90 | $147.25 | $85.24 | $0.00 | $0.00 |
| 2018 | $124.50 | $55.98 | $40.63 | $0.00 | $0.00 |
| 2019 | $31.20 | $17.72 | $40.28 | $0.00 | $76.09 |
| 2020 | $55.80 | $170.97 | $16.92 | $0.00 | $1,514.36 |
| 2021 | $32.40 | $19.31 | $19.30 | $0.00 | $0.00 |
| 2022 | $8.46 | $3.38 | $0.94 | $0.00 | $315.35 |
| 2023 | $1.83 | $18.49 | $0.02 | $0.00 | $0.00 |
| 2024 | $1.32 | $41.98 | $0.00 | $0.00 | $167.26 |
AI valuation
Our deep-learning model estimates Synlogic, Inc.'s (SYBX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $41.98
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.53
— upside
Graham-Dodd
—
— upside
Graham Formula
$167.26
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SYBX | Synlogic, Inc. | $1.62 | 18.95M | +2,491% | -67% | — | +10,225% | -0.69 | 1.26 | 2004.75 | 0.13 | — | 1.26 | 100.00% | -511875.00% | -291987.50% | -84.32% | -1348.15% | -48.98% | 0.00 | — | 2.80 | 2.67 | 0.85 | -7821.00% | -9976.00% | -3889.00% | -197.48% | -4.47 | -1042.70% | 0.00% | 0.00% | 75.91% | 0.07 | 0.09 | -352.75 | -35.87 |
| ALLR | Allarity Therapeutics, In… | $1.22 | 17.83M | — | — | — | — | -0.07 | 0.14 | — | 0.68 | — | 0.14 | 0.00% | — | — | -541.17% | 671.53% | -142.07% | 0.11 | -41.72 | 2.06 | 2.01 | 0.75 | -9974.00% | — | 3849.00% | -1036.16% | -1.60 | 441.86% | 0.00% | 0.00% | 1339.49% | 0.60 | 0.93 | — | -10.62 |
| BCTX | BriaCell Therapeutics Cor… | $10.22 | 19.25M | — | — | — | — | -0.64 | 0.95 | — | 0.03 | -1.44 | 0.96 | 0.00% | — | — | -343.04% | 1683.01% | -192.49% | 0.00 | -735.71 | 5.01 | 4.63 | 0.39 | 4450.00% | — | 1632.00% | -167.26% | -7.14 | 1742.76% | 0.00% | 0.00% | 56.64% | 0.03 | 0.03 | — | -8.16 |
| CING | Cingulate Inc. | $3.82 | 20.68M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| CRIS | Curis, Inc. | $1.42 | 17.75M | +255% | -18% | — | — | -0.42 | -3.06 | 1.68 | -0.03 | — | -1.23 | 99.10% | -408.34% | -397.77% | -634.71% | 156.53% | -73.20% | -0.49 | -72.43 | 1.39 | 1.23 | 0.40 | -2321.00% | 883.00% | 294.00% | -215.59% | -2.08 | 139.03% | 0.00% | 0.00% | 0.00% | -0.03 | -0.03 | 0.12 | -44.91 |
| CUPR | Cuprina Holdings (Cayman)… | $0.88 | 17.89M | — | — | — | — | — | — | — | — | — | — | -6.26% | -3404.85% | -3229.52% | 42.42% | 46.14% | -93.71% | -0.06 | -44.22 | 0.27 | 0.04 | -0.10 | 3922.00% | -5205.00% | -2191.00% | — | -0.20 | 35.27% | — | 0.00% | — | — | — | — | — |
| ENTO | Entero Therapeutics, Inc. | $4.22 | 20.11M | — | — | — | — | -0.43 | 0.13 | — | -491.36 | — | 0.14 | 0.00% | — | — | -58.82% | -0.05% | -39.13% | 0.00 | — | 3.03 | 0.01 | 1.47 | -8880.00% | — | -2842.00% | -119.84% | -0.33 | -31.51% | 0.00% | 0.00% | 0.00% | -490.90 | -0.83 | — | -2.37 |
| LEXX | Lexaria Bioscience Corp. | $1.08 | 21.17M | +2,546% | -61% | — | — | -1.57 | 6.26 | 26.52 | -1.43 | -3.89 | 6.98 | 83.20% | -1647.97% | -1686.00% | -216.06% | -846.18% | -182.65% | 0.04 | — | 2.32 | 1.56 | 0.14 | 4043.00% | 5205.00% | 10942.00% | -55.96% | -7.00 | -761.93% | 0.00% | 0.00% | 0.00% | -1.45 | -1.61 | 23.88 | -22.60 |
| LIXT | Lixte Biotechnology Holdi… | $4.08 | 18.56M | — | — | — | — | -0.75 | 3.26 | — | -0.47 | — | 3.26 | 0.00% | — | — | -148.73% | 1699.47% | -131.50% | 0.00 | — | 3.26 | 3.26 | 0.29 | -4023.00% | — | -2629.00% | -117.26% | -9.94 | 1505.28% | 0.00% | 0.00% | 0.00% | -0.46 | -0.52 | — | -68.09 |
| PCSA | Processa Pharmaceuticals,… | $0.34 | 17.12M | — | — | — | — | -0.12 | 0.87 | — | -0.03 | — | 0.87 | 0.00% | — | — | -354.51% | -2381.97% | -262.87% | 0.04 | — | 1.22 | 0.78 | 0.09 | -5436.00% | — | 3945.00% | -761.08% | -7.34 | -2223.27% | 0.00% | 0.00% | 1.08% | -0.03 | -0.03 | — | -49.42 |
About Synlogic, Inc.
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
- CEO
- Mary Beth Dooley
- Employees
- 1
- Beta
- 0.35
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.53 ÷ —) − 1 = — (DCF, example).